These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31365783)

  • 1. Synthesis and Preliminary Evaluation of [
    Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S
    ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and biological evaluation of[
    Malik N; Kornelsen R; McCormick S; Colpo N; Merkens H; Bendre S; Benard F; Sossi V; Schirrmacher R; Schaffer P
    Eur J Med Chem; 2021 Feb; 211():113005. PubMed ID: 33248850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2).
    Chen Z; Chen J; Mori W; Yi Y; Rong J; Li Y; Leon ERC; Shao T; Song Z; Yamasaki T; Ishii H; Zhang Y; Kokufuta T; Hu K; Xie L; Josephson L; Van R; Shao Y; Factor S; Zhang MR; Liang SH
    J Med Chem; 2024 Feb; 67(4):2559-2569. PubMed ID: 38305157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and In Vitro and In Vivo Evaluation of [
    Malik N; Gifford AN; Sandell J; Tuchman D; Ding YS
    Mol Imaging Biol; 2017 Dec; 19(6):837-845. PubMed ID: 28289968
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Chen X; Zhang Q; Zhang Y; Fang J; Jiang D; Mou Z; Liu H; Su R; Wang C; He F; Chen X; Xie F; Pan X; Li Z
    Eur J Med Chem; 2021 Mar; 214():113245. PubMed ID: 33582389
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
    Estrada AA; Liu X; Baker-Glenn C; Beresford A; Burdick DJ; Chambers M; Chan BK; Chen H; Ding X; DiPasquale AG; Dominguez SL; Dotson J; Drummond J; Flagella M; Flynn S; Fuji R; Gill A; Gunzner-Toste J; Harris SF; Heffron TP; Kleinheinz T; Lee DW; Le Pichon CE; Lyssikatos JP; Medhurst AD; Moffat JG; Mukund S; Nash K; Scearce-Levie K; Sheng Z; Shore DG; Tran T; Trivedi N; Wang S; Zhang S; Zhang X; Zhao G; Zhu H; Sweeney ZK
    J Med Chem; 2012 Nov; 55(22):9416-33. PubMed ID: 22985112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of [
    Wang M; Gao M; Xu Z; Zheng QH
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1351-1355. PubMed ID: 28223019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Leucine-Rich Repeat Kinase 2 In Vivo with
    Chen Z; Chen J; Chen L; Yoo CH; Rong J; Fu H; Shao T; Coffman K; Steyn SJ; Davenport AT; Daunais JB; Haider A; Collier L; Josephson L; Wey HY; Zhang L; Liang SH
    J Med Chem; 2023 Feb; 66(3):1712-1724. PubMed ID: 36256881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.
    Andersen MA; Sotty F; Jensen PH; Badolo L; Jeggo R; Smith GP; Christensen KV
    eNeuro; 2019; 6(6):. PubMed ID: 31685675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.
    Qin Q; Zhi LT; Li XT; Yue ZY; Li GZ; Zhang H
    CNS Neurosci Ther; 2017 Feb; 23(2):162-173. PubMed ID: 27943591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of [
    Yoo CH; Chen Z; Rani N; Chen J; Rong J; Chen L; Zhang L; Liang SH; Wey HY
    ACS Chem Neurosci; 2023 Feb; 14(3):370-377. PubMed ID: 36630128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
    Chen J; Chen Y; Pu J
    Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
    Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
    Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.
    Fuji RN; Flagella M; Baca M; Baptista MA; Brodbeck J; Chan BK; Fiske BK; Honigberg L; Jubb AM; Katavolos P; Lee DW; Lewin-Koh SC; Lin T; Liu X; Liu S; Lyssikatos JP; O'Mahony J; Reichelt M; Roose-Girma M; Sheng Z; Sherer T; Smith A; Solon M; Sweeney ZK; Tarrant J; Urkowitz A; Warming S; Yaylaoglu M; Zhang S; Zhu H; Estrada AA; Watts RJ
    Sci Transl Med; 2015 Feb; 7(273):273ra15. PubMed ID: 25653221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity.
    Bryce DK; Ware CM; Woodhouse JD; Ciaccio PJ; Ellis JM; Hegde LG; Kuruvilla S; Maddess ML; Markgraf CG; Otte KM; Poulet FM; Timmins LM; Kennedy ME; Fell MJ
    J Pharmacol Exp Ther; 2021 Apr; 377(1):11-19. PubMed ID: 33509901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2).
    Konstantinidou M; Oun A; Pathak P; Zhang B; Wang Z; Ter Brake F; Dolga AM; Kortholt A; Dömling A
    ChemMedChem; 2021 Mar; 16(6):959-965. PubMed ID: 33278061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.